GLUE

+ Watchlist + Portfolio

Monte Rosa Therapeutics, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $15.77
52-Week Range: $4.52 – $25.77
Market Cap: $1.26B
P/E (TTM): —
EPS (TTM): -1.64
Dividend Yield: —

Advanced Metrics

Price/Book: 2.59
PEG Ratio: —
Return on Equity: -42.66%
Return on Assets: -21.63%
Gross Margin: 0.00%
Operating Margin: -547.84%
Profit Margin: 0.00%
Current Ratio: 10.58
Debt/Equity: 0.08
Total Debt: $37.99M
Free Cash Flow: $-74.45M
Revenue Growth: -61.30%
Earnings Growth: —
Enterprise Value: $677.82M

GLUE Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$75.62M	$123.67M
Research & Development	$85.06M	$111.27M	$121.56M	$141.50M
Selling, General & Admin	$27.32M	$32.04M	$35.17M	$36.38M
Operating Expenses	$112.38M	$143.31M	$156.73M	$177.88M
Operating Income	-$112.38M	-$143.31M	-$81.11M	-$54.21M
EBITDA	-$108.64M	-$137.09M	-$72.99M	-$45.85M
Pretax Income	-$108.50M	-$135.01M	-$70.13M	-$39.72M
Income Tax	$0.00	$338.00K	$2.57M	-$1.10M
Net Income	-$108.50M	-$135.35M	-$72.70M	-$38.63M
Diluted EPS	-2.30	-2.63	-1.18	-0.59
Diluted Shares	47.23M	51.40M	61.51M	65.54M

GLUE Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$54.91M	$128.10M	$224.25M	$129.88M
Receivables	$7.66M	$505.00K	$173.00K	$11.60M
Current Assets	$275.89M	$236.21M	$377.44M	$393.19M
Total Assets	$342.39M	$303.75M	$438.73M	$448.66M
Current Liabilities	$25.57M	$46.59M	$156.95M	$64.21M
Total Debt	$47.00M	$46.04M	$42.72M	$39.19M
Total Liabilities	$70.98M	$124.50M	$215.80M	$215.60M
Retained Earnings	-$230.54M	-$365.89M	-$438.59M	-$477.21M
Shareholders' Equity	$271.41M	$179.25M	$222.94M	$233.06M
Working Capital	$250.32M	$189.62M	$220.49M	$328.97M

GLUE Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$92.47M	-$43.80M	$42.00M	-$22.80M
Capital Expenditure	-$12.91M	-$19.04M	-$3.99M	-$4.70M
Free Cash Flow	-$105.38M	-$62.84M	$38.01M	-$27.50M
Depreciation & Amortisation	$3.75M	$6.22M	$8.12M	$8.36M
Stock-Based Compensation	$11.66M	$16.67M	$18.13M	$18.86M
Investing Cash Flow	-$219.22M	$88.80M	-$44.45M	-$101.83M
Financing Cash Flow	$20.47M	$27.49M	$98.89M	$30.35M
Share Repurchases	—	-$116.00K	-$641.00K	-$357.00K
Net Change in Cash	-$291.22M	$72.49M	$96.44M	-$94.28M

GLUE Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$84.93M	$23.19M	$12.77M	$2.78M	$4.21M
Research & Development	$32.19M	$30.65M	$36.68M	$41.98M	$44.07M
Selling, General & Admin	$8.70M	$8.10M	$9.06M	$10.52M	$10.18M
Operating Expenses	$40.89M	$38.75M	$45.74M	$52.50M	$54.24M
Operating Income	$44.04M	-$15.55M	-$32.98M	-$49.72M	-$50.03M
EBITDA	$46.08M	-$13.43M	-$30.88M	-$47.63M	-$48.01M
Pretax Income	$47.71M	-$11.10M	-$30.26M	-$46.08M	-$44.45M
Income Tax	$822.00K	$1.20M	-$3.18M	$59.00K	$52.00K
Net Income	$46.88M	-$12.29M	-$27.08M	-$46.13M	-$44.50M
Diluted EPS	0.57	-0.20	-0.44	-0.70	-0.53
Diluted Shares	82.96M	61.72M	61.79M	65.54M	84.32M

GLUE Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$78.53M	$69.43M	$208.34M	$129.88M	$159.86M
Receivables	$1.41M	$2.37M	$4.96M	$11.60M	$4.61M
Current Assets	$332.28M	$299.46M	$401.82M	$393.19M	$677.55M
Total Assets	$393.20M	$359.59M	$459.84M	$448.66M	$736.43M
Current Liabilities	$59.22M	$41.85M	$61.44M	$64.21M	$71.04M
Total Debt	$41.86M	$41.13M	$40.17M	$39.19M	$39.06M
Total Liabilities	$118.04M	$91.51M	$214.00M	$215.60M	$214.51M
Retained Earnings	-$391.70M	-$404.00M	-$431.08M	-$477.21M	-$521.72M
Shareholders' Equity	$275.16M	$268.08M	$245.84M	$233.06M	$521.92M
Working Capital	$273.06M	$257.61M	$340.37M	$328.97M	$606.51M

GLUE Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$45.49M	-$34.72M	$100.43M	-$43.01M	-$37.37M
Capital Expenditure	-$1.59M	-$1.70M	-$651.00K	-$767.00K	-$1.87M
Free Cash Flow	-$47.08M	-$36.41M	$99.78M	-$43.78M	-$39.24M
Depreciation & Amortisation	$2.05M	$2.13M	$2.10M	$2.09M	$2.03M
Stock-Based Compensation	$5.30M	$4.89M	$4.36M	$4.31M	$5.95M
Investing Cash Flow	-$100.23M	$25.32M	$38.14M	-$65.07M	-$261.00M
Financing Cash Flow	$14.00K	$365.00K	$348.00K	$29.62M	$328.33M
Share Repurchases	—	—	—	-$357.00K	—
Net Change in Cash	-$145.71M	-$9.03M	$138.91M	-$78.46M	$29.97M

Market Snapshot

About

Monte Rosa Therapeutics, Inc. is a biotechnology company developing molecular glue degrader (MGD) medicines for targeted protein degradation. The company's proprietary QuEEN (Quantitative and Engineered Elimination of Neosubstrates) platform enables the discovery of small molecules that induce degradation of disease-causing proteins. Monte Rosa's lead program, MRT-2359, targets GSPT1 degradation for the treatment of MYC-driven cancers and is currently in clinical development. The company is advancing additional programs targeting oncology and immunology indications using its protein degradation technology. Monte Rosa's approach represents a novel therapeutic modality that goes beyond traditional enzyme inhibition by eliminating entire disease-relevant proteins. The company has established strategic collaborations with pharmaceutical partners to expand its pipeline and validate its technology platform across multiple therapeutic areas.